Jiangsu HengRui Medicine Co., Ltd.

New phase 1_2 trial NCT06385678 posted by Jiangsu HengRui Medicine Co., Ltd.: "A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation". New trial on a phase 1_2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 354 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 1_2 trial NCT06520488 posted by Jiangsu HengRui Medicine Co., Ltd.: "A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 351 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 1 trial NCT05533463 posted by Jiangsu HengRui Medicine Co., Ltd.: "Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation". New trial on a phase 1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 365 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.